• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Gastrointestinal

  • A Multicenter, Double-blind, Randomised Trial of the Intagastric Acid Control and Healing Effects of Esomeprazole Magnesium 10mg and 40mg Once Daily (NEXIUM) in the Treatment of Moderate and Severe Erosive Esophagitis (LA Classification Grades C & D).

Disease
gastrointestinal diseases
Drug Name
Nexium
Generic Name
esomeprazole
Sponsor
AstraZeneca
Drug Status
Approved Medicine
Phase
IV
Start Date
Jun 29, 2004
Study Name
D9612L00062
Study Id
D9612L00062
ClinicalTrials.gov ID
NCT00206180
Recruiting Status
Closed
Protocol Status
Not Available
Report
Jan 18, 1971
  • D9612L00062.pdf (45 KB)

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013